Pineridge Advisors’s GSK GSK Stock Holding History

Pineridge Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$129	Hold	3	–	–	﹤0.01%	443
2025 Q2	$115	Hold	3	–	–	﹤0.01%	544
2025 Q1	$116	Hold	3	–	–	﹤0.01%	488
2024 Q4	$101	Hold	3	–	–	﹤0.01%	613
2024 Q3	$123	Buy	+3	New	+$123	﹤0.01%	575

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pineridge Advisors's GSK Position: Q3 2025 in Review

Pineridge Advisors held its GSK (GSK) position steady in Q3 2025 at 3 shares worth $129. The position accounts for ﹤0.01% of the portfolio, ranked #443.

Pineridge Advisors first reported a position in GSK in Q3 2024 and has held it in 5 quarters since. 895 funds tracked by Wall St. Rank hold GSK as of Q3 2025.

Pineridge Advisors held 3 shares of GSK worth $129 as of Q3 2025.
Pineridge Advisors left its GSK share count unchanged in Q3 2025.
GSK made up ﹤0.01% of Pineridge Advisors's portfolio in Q3 2025, its #443 holding.
Pineridge Advisors first reported a position in GSK in Q3 2024 and has held it in 5 quarters since.
895 funds tracked by Wall St. Rank held GSK as of Q3 2025.

Based on Pineridge Advisors's 13F filing for Q3 2025, filed 4 Nov 2025.